Search clinical trials for: Adalimumab and placebo of fostamatinib

Total 161019 results

AstraZeneca

Terminated

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA) (OSKIRA -4)

Rheumatoid Arthritis

United States, Bulgaria, Czech Republic, Poland, Russian Federation, South Africa, United Kingdom, Hungary, Ukraine, Germany, Netherlands, Canada, Slovakia
AstraZeneca

Terminated

Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study (OSKIRA 4 SS)

Rheumatoid Arthritis

United States, Bulgaria, Russian Federation, South Africa, United Kingdom, Germany, Hungary, Netherlands, Canada, Czech Republic, Poland
Rigel Pharmaceuticals

Completed

Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

Pneumonia, Viral | Pneumonia | Covid19 | SARS (Severe Acute Respiratory Syndrome) | SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere | SARS Pneumonia

United States, Argentina, Brazil, Mexico
Rigel Pharmaceuticals

Completed

A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (FIT)

Immune Thrombocytopenic Purpura

United States, Australia, United Kingdom, Canada, Italy, Denmark, Hungary, Netherlands
Rigel Pharmaceuticals

Completed

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

Warm Antibody Autoimmune Hemolytic Anemia

United States, Spain, Canada, Australia, Norway, France, Belarus, Germany, Netherlands, Belgium, United Kingdom, Austria, Czechia, Georgia, Italy, Russian Federation, Serbia, Ukraine, Romania, Denmark, Hungary, Bulgaria
AstraZeneca

Completed

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding. (OSKIRA - 2)

Rheumatoid Arthritis

United States, Czech Republic, Spain, United Kingdom, Latvia, Lithuania, Romania, Ukraine, Canada, Israel, Portugal, Germany, South Africa, Serbia, India, Italy
Rigel Pharmaceuticals

Completed

A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (FIT)

Immune Thrombocytopenic Purpura

Spain, Norway, Poland, Czechia, Germany, United States, Austria, Bulgaria, Romania
AstraZeneca

Completed

Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis (Oskira ABPM)

Rheumatoid Arthritis

United States, Bulgaria, Czech Republic, Poland, South Africa, Ukraine, Germany
Rigel Pharmaceuticals

Completed

Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

IGA Nephropathy

United States, United Kingdom, Hong Kong, Taiwan, Austria, Germany
Rigel Pharmaceuticals

Completed

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3) (Taski-3)

Rheumatoid Arthritis

Belgium, United States, Colombia, France, Germany, Italy, Peru
Rigel Pharmaceuticals

Withdrawn

Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus (SOLEIL)

Systemic Lupus Erythematosus
AstraZeneca

Completed

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding. (OSKIRA - 1)

Rheumatoid Arthritis

United States, Brazil, Bulgaria, Peru, Poland, United Kingdom, Estonia, Hungary, Ukraine, Mexico, Argentina, Australia, Belgium, Chile, Slovakia, France, India
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Fostamatinib for Hospitalized Adults With COVID-19

Coronavirus Disease 2019

United States
Abbott

Completed

Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis

Arthritis | Psoriatic
Abbott

Completed

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy

Arthritis | Psoriatic
Rigel Pharmaceuticals

Withdrawn

Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy

IGA Nephropathy
Rigel Pharmaceuticals

Completed

A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA) (SOAR)

Warm Antibody Autoimmune Hemolytic Anemia

United States, Canada
Abbott

Completed

Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
Grupo Espanol de Trabajo en Enfermedad de Crohn...
Abbott; TFS Trial Form Support

Terminated

Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants (ADACAL)

Crohn's Disease | Mucosal Inflammation

Spain, France, Belgium
Abbott

Completed

Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
Abbott

Completed

Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)

Arthritis, Juvenile Idiopathic

United States, Belgium, Czech Republic, France, Germany, Italy, Slovakia, Spain
NEAT ID Foundation

Terminated

International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response (NECTAR)

COVID-19 | Coronavirus Infection | SARS-CoV2 Infection

Germany, Spain, Brazil, Italy, South Africa
Abbott

Completed

Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
Rigel Pharmaceuticals

Enrolling by invitation

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Warm Antibody Autoimmune Hemolytic Anemia

Spain, United States, Australia, Norway, Belarus, Germany, Netherlands, Belgium, Austria, Bulgaria, Czechia, France, Georgia, Italy, Russian Federation, Serbia, Ukraine, United Kingdom
Abbott

Completed

Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States, Argentina, Australia, Austria, Belgium, Canada, Czech Republic, Denmark, France, Germany, Hungary, Israel, New Zealand, Norway, Poland, Portugal, Spain, Switzerland
Abbott

Completed

Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis

Ankylosing Spondylitis

Canada
Abbott

Completed

Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis (ATLAS)

Ankylosing Spondylitis

United States
AbbVie (prior sponsor, Abbott)
Eisai Co., Ltd.

Completed

A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

Japan
Abbott

Completed

Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States, Denmark, Germany, Netherlands
Abbott

Completed

Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis (CHAMPION)

Psoriasis

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis

Enthesitis Related Arthritis (ERA)
Assistance Publique - Hôpitaux de Paris
Abbott

Completed

HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis

Giant Cell Arteritis

France
AbbVie (prior sponsor, Abbott)

Completed

Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa (PIONEER I)

Hidradenitis Suppurativa (HS)
Abbott
Eisai Co., Ltd.

Completed

A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
AbbVie (prior sponsor, Abbott)

Completed

Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa (PIONEER II)

Hidradenitis Suppurativa (HS)
AbbVie

Completed

Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease

Crohn's Disease
Abbott

Completed

Remission in Subjects With Crohn's Disease, 1 Year Phase (CLASSICII)

Crohn's Disease

United States
Peter Higgins
AbbVie

Withdrawn

Calprotectin-Directed Humira® Maintenance Therapy (CADHUM) (CADHUM)

Crohn's Disease

United States
Abbott
Eisai Co., Ltd.

Completed

A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease

Crohn's Disease

Japan
AstraZeneca

Completed

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist (OSKIRA - 3)

Rheumatoid Arthritis

United States, Czech Republic, Mexico, South Africa, Spain, United Kingdom, Germany, Argentina, Belgium, Canada, Hungary, Israel, Portugal, France, Brazil, Italy
AstraZeneca

Terminated

Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis (OSKIRA-Asia-1)

Rheumatoid Arthritis

Korea, Republic of, Vietnam, Hong Kong, Japan, Taiwan, Thailand
Imperial College London
Novartis; Imperial College Healthcare NHS Trust; Rigel Pharmaceuticals

Recruiting

Inflammatory Signal Inhibitors for COVID-19 (MATIS) (MATIS)

Pneumonia | Covid19 | Coronavirus

United Kingdom
Takeda

Completed

An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

Colitis, Ulcerative

United States, Belgium, Israel, Spain, Korea, Republic of, Taiwan, Netherlands, Australia, Denmark, Hungary, Russian Federation, Italy, Croatia, Hong Kong, Germany, Portugal, Serbia, Canada, Poland, Bulgaria, Ukraine, Colombia, Turkey, Czech... and more
Canadian Research & Education in Arthritis
AbbVie

Completed

Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA) (OKINADA)

Osteoarthritis, Knee

Canada
AbbVie

Completed

Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis

Axial Spondyloarthritis
Abbott

Completed

Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis

Ankylosing Spondylitis

China
Abbott
Eisai Co., Ltd.; Abbott Japan Co.,Ltd

Completed

A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease

Crohn's Disease

Japan
Abbott

Completed

Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing

Rheumatoid Arthritis

United States, Canada, Puerto Rico, Australia, Germany, United Kingdom
Abbott

Completed

Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis

Ulcerative Colitis

United States, Austria, Belgium, Canada, Czech Republic, Germany, Hungary, Italy, Netherlands, Poland, Puerto Rico, Slovakia, Sweden
National Heart, Lung, and Blood Institute (NHLBI)

Not yet recruiting

Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

Sickle Cell Disease | Sickle Cell Disorders | Hb-SS Disease | Hemoglobin S | Disease Sickle Cell Anemia | Hemoglobin Beta Thalassemia Disease

United States

Search clinical trials for: Adalimumab and placebo of fostamatinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations